Skip to main content
. 2018 Sep 26;362:k3609. doi: 10.1136/bmj.k3609

Table 5.

Relative risk of different histological types of ovarian cancer associated with hormonal contraception (full cohort), by categories of hormonal contraception use

Histology and use category No of person years No of cancer events Adjusted relative risk (95% CI)*
Epithelial ovarian cancer
Any epithelial ovarian cancer 902
 Never use 8 150 250 566 1.00
 Current or recent use 8 839 374 155 0.58 (0.47 to 0.70)
 Former use 4 505 157 181 0.75 (0.62 to 0.91)
Clear cell epithelial ovarian cancer 61
 Never use 8 150 250 41 1.00
 Current or recent use 8 839 374 9 0.59 (0.28 to 1.27)
 Former use 4 505 157 11 0.68 (0.32 to 1.41)
Endometrioid epithelial ovarian cancer 135
 Never use 8 150 250 93 1.00
 Current or recent use 8 839 374 21 0.58 (0.35 to 0.96)
 Former use 4 505 157 21 0.64 (0.38 to 1.06)
Mucinous epithelial ovarian cancer 204
 Never use 8 150 250 107 1.00
 Current or recent use 8 839 374 45 0.65 (0.44 to 0.97)
 Former use 4 505 157 52 0.96 (0.65 to 1.41)
Serous epithelial ovarian cancer 502
 Never use 8 150 250 325 1.00
 Current or recent use 8 839 374 80 0.55 (0.42 to 0.72)
 Former use 4 505 157 97 0.72 (0.56 to 0.93)
Non-epithelial ovarian cancer
No of ovarian cancer events 73
Never use 8 150 250 33 1.00
Current or recent use 8 839 374 21 0.64 (0.34 to 1.20)
Former use 4 505 157 19 1.09 (0.57 to 2.08)
Malignant tumour not otherwise specified
No of ovarian cancer events 274
Never use 8 150 250 172 1.00
Current or recent use 8 839 374 58 0.57 (0.41 to 0.80)
Former use 4 505 157 44 0.73 (0.50 to 1.05)
*

Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast or ovarian cancer.